Browsing by Author Yearley, Jennifer H

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2015PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patientsHaydu, Lauren; Hersey, Peter; Kakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Scolyer, Richard; Thompson, John; Vilain, Ricardo; Wilmott, James; Yearley, Jennifer H; Central Clinical School: Surgery; Northern Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: SurgeryPD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients, Clinical Cancer Research, vol.21, 14, 2015,pp 3140-3148
2015PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trialsHersey, Peter; Kakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; Madore, Jason; Menzies, Alexander Maxwel; Scolyer, Richard; Thompson, John; Vilain, Ricardo; Wilmott, James; Hyman, Jessica; Yearley, Jennifer H; Northern Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: SurgeryPD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials, Pigment Cell & Melanoma Research, vol.28, 3, 2015,pp 245-253
2015PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinomaBoyer, Michael; Cooper, Wendy Anne; Horvath, Lisa; Kao, Steven; McCaughan, Brian; O'Toole, Sandra; Scolyer, Richard; Vilain, Ricardo; Yip, Po Yee; Yu, Bing; Kohonen-Corish, Maija R.J.; Madore, Jason; Selinger, Christina; Tran, Thang N.; Yearley, Jennifer H; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Pathology; Medicine; Central Clinical School: MedicinePD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma, Lung Cancer, vol.89, 2, 2015,pp 181-188
2015Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastasesHersey, Peter; Kakavand, Hojabr; Long, Georgina; Scolyer, Richard; Thompson, John; Wilmott, James; Burke, Hazel; Vilain, Ricardo E; Yearley, Jennifer H; Northern Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryTumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases, Modern Pathology, vol.28, 12, 2015,pp 1535-1544